Continuous Versus Intermittent Nebulization Therapy in Acute Asthma Exacerbation at Emergency Department

Continuous Versus Intermittent Nebulization Therapy in Acute Asthma Exacerbation at Emergency Department: A Randomized Controlled Trial

The goal of this clinical is to compare treatment outcomes between continuous nebulization and intermittent therapy in the management of acute exacerbation of asthma in the emergency department(ED). Participants will random assign to either continuous or intermittent nebulization. In the continuous group, patients receive budesonide, fenoterol, ipratropium bromide, and normal saline continuously for an hour. In the intermittent group, the same medications are administer every 20 minutes for an hour. Measurements include symptom severity, respiratory rate, oxygen saturation, and pulmonary function tests. Primary endpoints are ED stay length, hospital admission, and ED revisit within 48 hours post-discharge. Adverse events are documented.

Inclusion Criteria:

• asthma exacerbation

Exclusion Criteria:

• life-threatening conditions requiring intubation
• allergy to steroid or its components
• patient under investigation of Corona Virus Disease, 2019 (COVID-19)
• pulmonary tuberculosis
• unable to cooperate for pulmonary function testing